Osteoporosis postmenopausal

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
3 Unique sponsors
4 Unique IMPs
2 Commercial trials
Drug classes (ATC)
N Neurology/Psychiatry (ATC N) 1
A Gastroenterology (ATC A) 1
M Musculoskeletal (ATC M) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Monoclonal antibody 1 substance
Monoclonal antibody (bone) 1 substance
Phase III: 1 Phase II: 1 Phase IV: 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial
  • Curateq Biologics Private Limited Commercial
    COLECALCIFEROL; DENOSUMAB
    2023-503790-37-00 6 countries 2024 n=615
    Ended

Phase II

1 trial
  • Angitia Inc. Ltd. Commercial
    AGA2118
    2024-515610-41-00 4 countries 2025 n=260
    Recruiting

Phase IV

1 trial
  • Ospedale Galeazzi S.p.A. Academic
    DENOSUMAB; ROMOSOZUMAB
    2025-522592-29-00 1 country n=60
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Angitia Inc. Ltd. Commercial 1 Phase II 1
Curateq Biologics Private Limited Commercial 1 Phase III 0
Ospedale Galeazzi S.p.A. Academic 1 Phase IV 0
New trials by year
2024
1
2025
1
← All indication landscapes